Tivic completes enrollment in vagus nerve stimulation device optimization study

Tivic Health (TIVC) announced that full enrollment has been completed in the optimization study for Tivic Health’s patent pending, non-invasive vagus nerve stimulation device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the study is to identify device parameters that optimally influence autonomic nervous system (ANS) function. These include the frequency and the duration of potential treatments. Tivic Health plans to use these results to prioritize clinical indications that the company expects to carry forward into further testing and commercial development. The trial is expected to be completed in early first quarter 2025.